Genetic Predisposition Impacts Clinical Changes in a Lifestyle Coaching Program

Zubair, Niha; Conomos, Matthew P.; Hood, Leroy; Omenn, Gilbert S.; Price, Nathan D.; Spring, Bonnie; Magis, Andrew T.; Lovejoy, Jennifer C.

doi:10.1038/s41598-019-43058-0

Cited by 55 publications

(62 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We interrogated the associations between plasma concentrations of sACE2 and biomarkers of metabolic syndrome (body mass index, BMI; blood pressure; glycemic markers; and lipid levels), adiposity (plasma leptin and serum adiponectin), inflammation (high-sensitivity C-reactive protein, hsCRP, white blood cell count, and interleukin-8), and liver damage (alanine aminotransferase, aspartate transaminase, and gamma-glutamyl-transferase, GGT) in a large cohort of participants in a commercial wellness program who had undergone comprehensive multi-omic profiling ( N = 2051; 1238 women and 813 men, aged 22 to 87 years, M = 47.3, SD = 11.71) (see [ 5 ] for details). Clinical laboratory tests were performed in CLIA-certified laboratories by Quest Diagnostics or LabCorp.…”

mentioning

confidence: 99%

Plasma levels of soluble ACE2are associated with sex, Metabolic Syndrome, and its biomarkers in a large cohort, pointing to a possible mechanism for increased severity in COVID-19

et al. 2020

Self Cite

View full text Add to dashboard Cite

To the Editor: Patients at high risk for mortality from COVID-19, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are more likely to be older and male and have chronic diseases such as hypertension, diabetes, cardiovascular, and chronic lung disease [1, 2]. Although the mechanisms behind these associations are poorly understood, this increased risk could be partly associated with increased expression of the cellular receptor of SARS-CoV-2, angiotensin-converting enzyme-2, found at elevated levels in older individuals, men, and in cardiovascular and inflammatory conditions [3, 4]. It maintains homeostasis of the renin-angiotensin system and converts angiotensin II to angiotensin 1-7, which has vasodilatory and anti-inflammatory properties. The membrane-bound form (mACE2) is highly expressed in the heart, airways, kidney, and liver tissue, and the enzymatically active soluble form (sACE2) is generated in response to inflammatory signals and disease via mACE2 shedding. We interrogated the associations between plasma concentrations of sACE2 and biomarkers of metabolic syndrome (body mass index, BMI; blood pressure; glycemic markers; and lipid levels), adiposity (plasma leptin and serum adiponectin), inflammation (high-sensitivity Creactive protein, hsCRP, white blood cell count, and interleukin-8), and liver damage (alanine aminotransferase, aspartate transaminase, and gamma-glutamyltransferase, GGT) in a large cohort of participants in a commercial wellness program who had undergone comprehensive multi-omic profiling (N = 2051; 1238 women and 813 men, aged 22 to 87 years, M = 47.3, SD = 11.71) (see [5] for details). Clinical laboratory tests were performed in CLIA-certified laboratories by Quest Diagnostics or LabCorp. Plasma sACE2 and leptin levels were measured via proximity extension immunoassaying using Olink® Cardiovascular II proteomics panel. Analyses were performed using transformed and scaled biomarker values in a robust linear regression framework controlling for age, sex (where appropriate), 8 genetic principal components, smoking, vendor, season, use of diabetes, cholesterol-lowering, and ACE-inhibitor medications. Confirming results from recent studies [3, 4], we found higher plasma sACE2 levels in men compared to women (P = 2 × 10 −16), and in older individuals (P = 8.6 × 10 −11), with the age association more pronounced in women (for the interaction, P int = 0.02). We found higher levels of sACE2 in post-menopausal women, compared to premenopausal women (P = 0.02; see Fig. 1).

show abstract

mentioning

confidence: 99%

Plasma levels of soluble ACE2are associated with sex, Metabolic Syndrome, and its biomarkers in a large cohort, pointing to a possible mechanism for increased severity in COVID-19

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is unclear what the costs will be of assembling such a package of data and providing effective coaching about what the data means for the individual. Start-up companies which are operating in this arena in the USA have shown that it is technologically feasible [58] but have struggled with the economies of scale needed to make it commercially viable, so whether national health authorities could adopt this approach more successfully remains unclear. However, like most technological solutions, it can reasonably be expected that costs will fall significant-DOI: 10.1159/000503141 ly with time and with adoption at scale.…”

Section: Discussionmentioning

confidence: 99%

Precision Medicine and Vaccination of Older Adults: From Reactive to Proactive (A Mini-Review)

Doherty¹,

Pasquale²,

Michel³

et al. 2019

Gerontology

View full text Add to dashboard Cite

Key Messages• As populations age, the total disease burden due to non-communicable or chronic conditions in older adults increases: infectious diseases are a significant and under-appreciated contributor to poor outcomes in this population. • Vaccination has been shown to dramatically improve outcomes in patients with chronic comorbidities but is almost always under-used in adults. • If vaccination programs for adults reached their full potential, the risk of hospitalization or death due to both infectious and non-infectious diseases could be effectively lowered. • A precision medicine approach, which integrates vaccination as part of a package of health interventions targeting an individual's needs, may offer a promising complementary approach to improving coverage and reducing the total burden of disease in addition to current public health interventions. AbstractAs populations age globally, the health of older adults is looming larger on the agendas of public health bodies.

show abstract

“…For example, the Institute for Systems Biology generated a deeply phenotyped longitudinal data set from a real-world population for over 6200 individuals across the wellness to disease spectra who participated in a consumer wellness program between 2015 and 2019 and shared their deidentified data for research purposes. 59,60 For each individual, a personal, dense, dynamic, data (PD3) cloud that included genomics and longitudinal measures of clinical laboratories, metabolomics, proteomics, and gut microbiomics was generated. This also included data from wearable monitors and questionnaires to capture user-reported measures of lifestyle, physical health, and mental health.…”

Section: The Need For Deeply Phenotyped Data Setsmentioning

confidence: 99%

Precision Medicine in Pancreatic Disease—Knowledge Gaps and Research Opportunities

et al. 2019

View full text Add to dashboard Cite

A workshop on research gaps and opportunities for Precision Medicine in Pancreatic Disease was sponsored by the National Institute of Diabetes and Digestive Kidney Diseases on July 24, 2019, in Pittsburgh. The workshop included an overview lecture on precision medicine in cancer and 4 sessions: (1) general considerations for the application of bioinformatics and artificial intelligence; (2) omics, the combination of risk factors and biomarkers; (3) precision imaging; and (4) gaps, barriers, and needs to move from precision to personalized medicine for pancreatic disease. Current precision medicine approaches and tools were reviewed, and participants identified knowledge gaps and research needs that hinder bringing precision medicine to pancreatic diseases. Most critical were (a) multicenter efforts to collect large-scale patient data sets from multiple data streams in the context of environmental and social factors; (b) new information systems that can collect, annotate, and quantify data to inform disease mechanisms; (c) novel prospective clinical trial designs to test and improve therapies; and (d) a framework for measuring and assessing the value of proposed approaches to the health care system. With these advances, precision medicine can identify patients early in the course of their pancreatic disease and prevent progression to chronic or fatal illness. Lowe et al.

show abstract

Genetic Predisposition Impacts Clinical Changes in a Lifestyle Coaching Program

Cited by 55 publications

References 26 publications

Plasma levels of soluble ACE2are associated with sex, Metabolic Syndrome, and its biomarkers in a large cohort, pointing to a possible mechanism for increased severity in COVID-19

Plasma levels of soluble ACE2are associated with sex, Metabolic Syndrome, and its biomarkers in a large cohort, pointing to a possible mechanism for increased severity in COVID-19

Precision Medicine and Vaccination of Older Adults: From Reactive to Proactive (A Mini-Review)

Precision Medicine in Pancreatic Disease—Knowledge Gaps and Research Opportunities

Contact Info

Product

Resources

About